Cargando…
Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs
With more human papillomavirus (HPV) virus-like particle (VLP) vaccines to hit the market in future, a monoclonal antibody (mAb) with preferably comparable reactivity against vaccines from different expression systems and bioprocesses is urgently needed for the potency characterization. Among all mA...
Autores principales: | Huang, Weijin, He, Maozhou, Ning, Tingting, Nie, Jianhui, Zhang, Feng, Zheng, Qingbing, Zhang, Rui, Xu, Ying, Gu, Ying, Li, Shaowei, Wang, Youchun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511963/ https://www.ncbi.nlm.nih.gov/pubmed/33042588 http://dx.doi.org/10.1038/s41541-020-00236-w |
Ejemplares similares
-
Scalable Production of HPV16 L1 Protein and VLPs from Tobacco Leaves
por: Zahin, Maryam, et al.
Publicado: (2016) -
SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023) -
Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus
por: Parrington, Helen M., et al.
Publicado: (2023) -
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
por: Capuano, Cristina, et al.
Publicado: (2021) -
Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs
por: Rhee, Beomseok, et al.
Publicado: (2022)